The agency approved Revuforj after reviewing data from a single-arm cohort of the open-label AUGMENT-101 trial, involving approximately 100 patients at least 30 days old with relapsed or refractory ...
MEDIA RELEASEAfqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback